blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3209691

EP3209691 - COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES [Right-click to bookmark this link]
Former [2017/35]METHOD AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES
[2020/07]
StatusPatent revoked
Status updated on  07.10.2025
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  12.06.2020
FormerGrant of patent is intended
Status updated on  26.01.2020
FormerExamination is in progress
Status updated on  02.02.2018
FormerRequest for examination was made
Status updated on  28.07.2017
FormerThe international publication has been made
Status updated on  15.03.2017
Most recent event   Tooltip10.10.2025Revocation of patentpublished on 12.11.2025  [2025/46]
Applicant(s)For all designated states
OSE Immunotherapeutics
22 Boulevard Benoni Goullin
44200 Nantes / FR
[2020/29]
Former [2017/35]For all designated states
OSE Immunotherapeutics
22 Boulevard Benoni Goullin
44200 Nantes / FR
Inventor(s)01 / POIRIER, Nicolas
1 chemin du Passe-Temps
F-44119 Treillières / FR
02 / VANHOVE, Bernard
72 bis rue Henri Barbusse
F-44400 Rezé / FR
 [2017/35]
Representative(s)Ernest Gutmann - Yves Plasseraud S.A.S.
C/o Plasseraud IP
104 Rue de Richelieu
CS 92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2020/29]Ernest Gutmann - Yves Plasseraud S.A.S.
66, rue de la Chaussée d'Antin
75009 Paris / FR
Former [2017/35]Gevers & Orès
41 avenue de Friedland
75008 Paris / FR
Application number, filing date15794641.921.10.2015
[2017/35]
WO2015IB58124
Priority number, dateEP2014019037024.10.2014         Original published format: EP 14190370
[2017/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016063233
Date:28.04.2016
Language:EN
[2016/17]
Type: A1 Application with search report 
No.:EP3209691
Date:30.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.04.2016 takes the place of the publication of the European patent application.
[2017/35]
Type: B1 Patent specification 
No.:EP3209691
Date:15.07.2020
Language:EN
[2020/29]
Search report(s)International search report - published on:EP28.04.2016
ClassificationIPC:C07K16/28, A61K39/00
[2017/35]
CPC:
C07K16/2896 (EP,US); A61K39/39558 (US); A61K45/06 (US);
A61P17/02 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P35/00 (EP); A61P35/04 (EP); A61P37/04 (EP);
A61P37/06 (EP); A61P43/00 (EP); C07K16/2803 (EP,US);
G01N33/5011 (US); G01N33/5023 (US); A61K2039/505 (EP,US);
C07K2317/73 (EP,US); C07K2317/75 (EP,US); C07K2317/76 (EP,US);
G01N2500/02 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/35]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:ZUSAMMENSETZUNGEN ZUR INDUZIERUNG DER DIFFERENZIERUNG VON AUS MYELOIDEN GEWONNENEN SUPPRESSORZELLEN ZUR BEHANDLUNG VON KREBS UND INFEKTIONSKRANKHEITEN[2020/07]
English:COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES[2020/07]
French:COMPOSITIONS POUR INDUIRE LA DIFFÉRENCIATION DE CELLULE SUPPRESSIVES DÉRIVÉES DE MYÉLOÏDE POUR TRAITER LE CANCER ET LES MALADIES INFECTIEUSES[2020/07]
Former [2017/35]VERFAHREN UND ZUSAMMENSETZUNGEN ZUR INDUZIERUNG DER DIFFERENZIERUNG VON AUS MYELOIDEN GEWONNENEN SUPPRESSORZELLEN ZUR BEHANDLUNG VON KREBS UND INFEKTIONSKRANKHEITEN
Former [2017/35]METHOD AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES
Former [2017/35]PROCÉDÉ ET COMPOSITIONS PERMETTANT L'INDUCTION D'UNE DIFFÉRENCIATION DES CELLULES MYÉLOÏDES SUPPRESSIVES POUR TRAITER LE CANCER ET LES MALADIES INFECTIEUSES
Entry into regional phase02.05.2017National basic fee paid 
02.05.2017Designation fee(s) paid 
02.05.2017Examination fee paid 
Examination procedure02.05.2017Examination requested  [2017/35]
02.05.2017Date on which the examining division has become responsible
05.02.2018Despatch of a communication from the examining division (Time limit: M06)
25.07.2018Reply to a communication from the examining division
26.10.2018Despatch of a communication from the examining division (Time limit: M04)
22.02.2019Reply to a communication from the examining division
10.01.2020Cancellation of oral proceeding that was planned for 28.01.2020
27.01.2020Communication of intention to grant the patent
28.01.2020Date of oral proceedings (cancelled)
28.05.2020Fee for grant paid
28.05.2020Fee for publishing/printing paid
28.05.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20177260.5  / EP3783027
EP25219878.3
Opposition(s)Opponent(s)01  15.04.2021  19.04.2021  ADMISSIBLE
Byondis B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
van Gent, Marieke
Byondis B.V.
Intellectual Property Department
Microweg 22
6545 CM Nijmegen / NL
 [2025/13]
Former [2021/21]
Opponent(s)01  15.04.2021  19.04.2021  ADMISSIBLE
Byondis B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
't Hoen-van der Hoogt, Cornelia Catharina
Byondis B.V.
Microweg 22
6545 CM Nijmegen / NL
07.05.2021Invitation to proprietor to file observations on the notice of opposition
16.09.2021Reply of patent proprietor to notice(s) of opposition
24.05.2023Date of oral proceedings
21.06.2023Despatch of interlocutory decision in opposition
21.06.2023Despatch of minutes of oral proceedings
30.06.2025Despatch of communication that the patent will be revoked
03.07.2025Legal effect of revocation of patent [2025/46]
Appeal following opposition21.08.2023Appeal received No.  T1505/23
21.08.2023Payment of appeal fee
27.10.2023Statement of grounds filed
03.07.2025Result of appeal procedure: revocation of the patent
01.10.2025Despatch of the decision of the Board of Appeal
17.08.2023Appeal received No.  T1505/23
17.08.2023Payment of appeal fee
19.10.2023Statement of grounds filed
03.07.2025Result of appeal procedure: revocation of the patent
01.10.2025Despatch of the decision of the Board of Appeal
03.07.2025Date of oral proceedings
Fees paidRenewal fee
31.07.2017Renewal fee patent year 03
25.10.2018Renewal fee patent year 04
25.09.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL15.07.2020
CY15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
MK15.07.2020
MT15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IE21.10.2020
LU21.10.2020
IS15.11.2020
PT16.11.2020
[2022/32]
Former [2022/28]AL15.07.2020
CY15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
MT15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IE21.10.2020
LU21.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/46]AL15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IE21.10.2020
LU21.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/36]AL15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
LU21.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/31]AL15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
RO15.07.2020
RS15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
LU21.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/25]AL15.07.2020
EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
RO15.07.2020
RS15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/22]EE15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
RO15.07.2020
RS15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/10]FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
RS15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/09]FI15.07.2020
LT15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
PT16.11.2020
Former [2021/08]FI15.07.2020
LT15.07.2020
BG15.10.2020
NO15.10.2020
PT16.11.2020
Former [2021/07]FI15.07.2020
LT15.07.2020
NO15.10.2020
Cited inInternational search[XYI] WO2013056352  (UNIV HEALTH NETWORK et al.) [X] 1-13 * the whole document *[Y] 18,19 [I] 14-17
 [Y] WO2012149416  (UNIV SOUTHERN CALIFORNIA et al.) [Y] 18,19 * the whole document *
 [XYI]   CHAO M P ET AL: "Response: Mechanisms of targeting CD47-SIRP[alpha] in hematologic malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 119, no. 18, 3 May 2012 (2012-05-03), pages 4334 - 4335, XP009160297, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2012-02-411249 [X] 1-13 * the whole document *[Y] 18,19 [I] 14-17

DOI:   http://dx.doi.org/10.1182/blood-2012-02-411249
 [A]   JORDI C OCHANDO ET AL: "Myeloid-derived suppressor cells in transplantation and cancer", IMMUNOLOGIC RESEARCH, HUMANA PRESS INC, NEW YORK, vol. 54, no. 1 - 3, 26 April 2012 (2012-04-26), pages 275 - 285, XP035126289, ISSN: 1559-0755, DOI: 10.1007/S12026-012-8335-1 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1007/s12026-012-8335-1
OppositionWO2013056352
 WO2015138600
 US201461951226
 WO2009131453
 EP1637598
 US202015518803
 WO2013109752
   YANAGITA TADAHIKO, MURATA YOJI, TANAKA DAISUKE, MOTEGI SEI-ICHIRO, ARAI ERI, DANIWIJAYA EDWIN WIDYANTO, HAZAMA DAISUKE, WASHIO KEN: "Anti-SIRP antibodies as a potential new tool for cancer immunotherapy", JCI INSIGHT, vol. 2, no. l, 2017, pages 1 - 15, XP055421877

DOI:   http://dx.doi.org/10.1172/jci.insight.89140
   ANONYMOUS: "Anti-SHPS-1 Antibody, clone P84 clone P84", ANTI-SHPS-1 ANTIBODY, 2021, pages 1 - 3, XP055963015
   ZHAO XI WEN, VAN BEEK ELLEN M., SCHORNAGEL KARIN, VAN DER MAADEN HANS, VAN HOUDT MICHEL, OTTEN MARIELLE A., FINETTI PASCAL, VAN EG: "CD47signal regulatory protein- (SIRP) interactions form a barrier for antibody-mediated tumor cell destruction", PNAS USA, vol. 108, no. 45, 2011, pages 18342 - 18347, XP055055636

DOI:   http://dx.doi.org/10.1073/pnas.1106550108
   ABE: "Abstract B1139 Blockade of CD47-Signaling regulatory protein alpha signalling enhances the macrophage phagocytic activity against cancer cells", TRANSPLANTATION, vol. 98, no. 1, 15 July 2014 (2014-07-15), pages 313, XP055963000
   MARTINA SEIFFERT, PETER BROSSART, CHARLES CANT, MARINA CELLA, MARCO COLONNA, WOLFRAM BRUGGER, LOTHAR KANZ, AXEL ULLRICH, HANS-JOR: "Signal-regulatory protein (SIRP) but not SIRP is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38hematopoietic cells", BLOOD, vol. 97, no. 9, 2001, pages 2741 - 2749, XP055056736

DOI:   http://dx.doi.org/10.1182/blood.V97.9.2741
   VONDERHEIDE: "CD47 blockade as another immune checkpoint therapy for cancer", NATURE MEDICINE, vol. 21, no. 10, 7 October 2015 (2015-10-07), pages 1122 - 1123, XP055559428

DOI:   http://dx.doi.org/10.1038/nm.3965
   MCCRACKEN MELISSA N., CHA ADRIEL C., WEISSMAN IRVING L.: "Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 Don't Eat Me Signals", CLINICAL CANCER RESEARCH, vol. 21, no. 16, 26 June 2015 (2015-06-26), pages 3597 - 3601, XP055330326

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-14-2520
   SRIVASTAVA MINU K., DUBINETT STEVEN, SHARMA SHERVEN: "Targeting MDSCs enhance therapeutic vaccination responses against lung cancer", ONCOIMMUNOLOGY, vol. 1, no. 9, 2012, pages 1650 - 1651, XP055458054

DOI:   http://dx.doi.org/10.4161/onci.21970
   BORCH TROELS H., DONIA MARCO, ANDERSEN MADS H., SVANE INGE M.: "Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies", DRUG DISCOVERY TODAY, vol. 20, no. 9, September 2015 (2015-09-01), pages 1127 - 1134, XP002791774

DOI:   http://dx.doi.org/10.1016/j.drudis.2015.07.003
   MAKAROVA-RUSHER OXANA V., MEDINA-ECHEVERZ JOS, DUFFY AUSTIN G., GRETEN TIM F.: "The yin and yang of evasion and immune activation in HCC", JOURNAL OF HEPATOLOGY, vol. 62, 27 February 2015 (2015-02-27), pages 1420 - 1429, XP029173095

DOI:   http://dx.doi.org/10.1016/j.jhep.2015.02.038
   WILLINGHAM STEPHEN B., VOLKMER JENS-PETER, GENTLES ANDREW J., SAHOO DEBASHIS, DALERBA PIERO, MITRA SIDDHARTHA S., WANG JIAN, CONTR: "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors", PNAS USA, vol. 190, no. 17, 2012, pages 6662 - 6667, XP055029983

DOI:   http://dx.doi.org/10.1073/pnas.1121623109
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.